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Abstract
Purpose In the integrated analysis of phase III head-to-head trials in patients with advanced solid tumors, denosumab demon-
strated superiority over zoledronic acid in preventing skeletal-related events (SREs). Regular and continued drug use
(persistence) is a precondition of clinical efficacy; persistence in real-life is yet undetermined for denosumab.
Methods This was a single-arm, prospective, observational, non-interventional study in 598 patients with bone metastases from
breast, prostate, lung, or other solid tumors treated with denosumab every four weeks in real-world clinical practice in Austria,
Czech Republic, Hungary, Slovakia, and Bulgaria. Persistence was defined as denosumab administration at ≤ 35-day intervals
over 24 or 48 weeks, respectively.
Results Previous SREs were found in 10.9% of patients. 62.6% were persistent over 24 weeks and 40.1% over 48 weeks. The
Kaplan-Meier median (95% CI) time to non-persistence was 274.0 days (232.0, 316.0). The most frequent reason for non-
persistence was delayed administration. There was a trend towards weaker analgesics over time, with approximately 60% of
patients not requiring any analgesics. Serum calcium remained within the normal range throughout the study. Adjudicated
osteonecrosis of the jaw was documented in three patients with an incidence per patient-year (95% CI) of 0.012 (0.004, 0.029).
Conclusions Most patients received denosumab regularly once every four weeks over 24 weeks of treatment. Non-persistence
was mainly due to delayed administration. The incidence of adverse drug reactions, especially of osteonecrosis of the jaw, was in
line with expectations from previous studies.
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Introduction
Bone metastases represent a frequent complication of cancer,
with more than 1.5 million affected patients worldwide [1].
Clinically important skeletal complications are the result of
osteoclast-mediated bone destruction [2, 3] often leading to
severe pain, decreased quality of life, instability, and neuro-
logic compromise [4].
Denosumab, a fully human monoclonal antibody of the
IgG2 subtype, inhibits the receptor activator of nuclear fac-
tor κB ligand (RANKL) on bone cells. In its oncological
formulation, denosumab is indicated in Europe for the pre-
vention of skeletal-related events (SREs; pathological frac-
ture, radiation to bone, spinal cord compression, or surgery
to bone) in adults with advanced malignancies involving
the bone and for the treatment of adults and skeletally ma-
ture adolescents with giant cell tumor of bone that is
unresectable or where surgical resection is likely to result
in severe morbidity [5].
In the integrated analysis of three pivotal, phase III head-to-
head trials, denosumab was superior in preventing SREs com-
pared with zoledronic acid [6]. Yet, in real-world clinical rou-
tine, irregular administration or unplanned interruption or dis-
continuation of therapy may impact the therapeutic potential
of denosumab in comparison with the efficacy demonstrated
in controlled clinical trials. As per International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) defi-
nition, medication compliance refers to the act of conforming
to the recommendations made by the provider with respect to
timing, dosage, and frequency of medication taking (= per-
centage of doses taken as prescribed). Medication persistence
refers to the act of conforming to a recommendation of con-
tinuing treatment for the prescribed length of time (= days
medication was taken without exceeding permissible inter-
vals) [7].
The extent to which poor compliance and persistence
affect clinical efficacy is a complex issue. From a payer’s
perspective, low compliance and/or persistence often works
in two directions: they reduce medication costs but subse-
quently increase health care resource utilization. Although
this cannot necessarily be assumed in all settings, a rela-
tionship between bone metastasis–related SREs and addi-
tional inpatient stays and an increased use of surgical or
other procedures has been demonstrated [8]. To date, the
availability of real-life data assessing persistence with
denosumab in health care settings in the countries of inter-
est is limited. The convenience of a subcutaneous route of
administration and the positive risk/benefit profile of
denosumab may result in a high persistence not only in
controlled clinical trials but also in real-life clinical prac-
tice. The objectives of the present study were to obtain
relevant information on real-world practice conditions of
denosumab use and on persistence with the drug.
Methods
Study design
This was a single-arm, prospective, observational, non-inter-
ventional, multi-center cohort study in patients with solid tu-
mors and bone metastases in Austria and selected Central and
Eas te rn European (CEE) coun t r ies , namely the
Czech Republic, Hungary, Slovakia, and Bulgaria. As this
was a non-interventional study, no laboratory, diagnostic, or
therapeutic procedures other than those performed as part of
the patient’s routine care were required. Patients were ob-
served from enrollment (having received the first dose of
denosumab as per standard of care within 28 days prior to
enrollment) until the last denosumab dose administered up
to a maximum of 48 weeks after the first administration plus
30 days of safety follow-up.
Eligibility criteria
Patients treated with the denosumab formulation XGEVA®
(Amgen Europe B.V., Breda, The Netherlands) at a dose of
120 mg subcutaneously once every four weeks, in accordance
with the—at time of enrollment—most current version of the
EuropeanMedicines Agency’s summary of medicinal product
characteristics (SmPC) were eligible to participate in this
study. In addition, they had to meet the following criteria:
adult age (≥ 18 years) at enrollment; a diagnosis of breast,
prostate, lung, or other solid tumor with confirmed bone me-
tastasis; an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 2; administration of the first
denosumab dose ever within 28 days prior to enrollment.
Patients were excluded: if they had a diagnosis of multiple
myeloma (not an approved indication at the time of study
conduct), were previously treated for SRE prevention with
bisphosphonates or other antiresorptive agents for more than
6 months, were previously treated with radionuclides (e.g.,
strontium-98, samarium-153, radium-223), were enrolled in
an investigational drug trial for the treatment and/or preven-
tion of bone metastases and SREs, or had contraindications to
denosumab. Patients in a trial related to the treatment of their
underlying cancer or in long-term follow-up studies were
eligible.
Study objectives
The primary objective was to estimate the persistence with
denosumab treatment as per routine clinical practice at
24 weeks. Secondary objectives were to estimate the persis-
tence with denosumab at 48 weeks and the time to and reasons
of non-persistence, to describe patient demographics, disease
characteristics, concomitant anticancer therapy and medical
history, and calcium and vitamin D supplementation patterns.
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Exploratory objectives included the description of pain med-
ication patterns and patient-reported outcomes according to
the EQ-5D questionnaire in countries where this was accepted
by local authorities and reasons for the choice of denosumab
over other options.
Reporting of adverse drug reactions
Safety data related to denosumab were collected for up to
30 days after the last denosumab dose. Osteonecrosis of the
jaw (ONJ) was regarded as an event of special interest. All
suspected events of ONJ were documented and reported as
serious adverse drug reactions (ADRs), regardless of whether
serious criteria could be assigned and whether causal relation-
ship with denosumab established. Any suspected case of ONJ
was reviewed by an independent adjudication panel to con-
firm or reject the ONJ categorization.
Ethics
This study compliedwith all relevant national requirements on
a country-by-country basis. Written informed consent was ob-
tained from the patient or legally acceptable representative.
National ethics committee approval of the protocol and in-
formed consent form was obtained before recruitment of pa-
tients or any data collection.
Statistical analysis
No formal hypothesis was tested. For continuous variables,
descriptive statistics including the mean, standard devia-
tion (SD), median, first (Q1) and third (Q3) quartiles, and
minimum and maximum values (range) were presented
along with 95% two-sided confidence intervals (CIs),
where appropriate. Missing values of continuous variables
were counted as “Missing”. For categorical variables, the
number and percentage of patients in each category were
reported. For binary variables, the number and percentage
of patients were reported, along with exact two-sided CIs,
where appropriate. Missing results were excluded from the
calculation of CIs; however, the number and percentage of
patients with missing results were given for categorical
data. The statistical analyses were based on the full analy-
sis set (FAS), which consisted of the enrolled patients who
met eligibility criteria and received at least one dose of
denosumab. The Kaplan-Meier method and Cox propor-
tional hazards model were used to analyze the data for time
to non-persistence. For statistical analysis, the SAS System
9.4 was used.
“Persistence” measured the regularity and duration of
continuous use of denosumab and was defined as continu-
ous use from the first administration without exceeding a
maximum permissible 35-day gap (4 weeks plus 7 days)
until the last date of administration (discontinuation date),
disenrollment (due to death or loss to follow-up), or end of
the study period. Time to non-persistence was calculated as
the time between the first injection and the last injection
received during the period where the patient was still clas-
sified as persistent plus 28 days. When the predefined time
window between injections of a maximum of 35 days was
exceeded, a drop-down window of reasons for dose inter-
ruption opened in the electronic case report form, which
were documented as reasons for non-persistence.
Additionally, the reason “violation of permissible time
window” was documented automatically when the
predefined time window of a maximum of 35 days was
exceeded based on the documented dates of administration.
Results
Patient disposition
A total of 598 patients (FAS) were analyzed (Fig. 1; Table S1,
online supplemental material). Of these, 294 patients were
from Austr ia , 130 from Bulgar ia , 103 from the
Czech Republic, 54 from Slovakia, and 17 from Hungary.
Of 598 patients initiated with denosumab, 451 (75.4%)
completed 24 weeks of observation and 147 (24.6%)
discontinued prematurely. The main reasons for premature
study discontinuation were death (9.9%, n = 59), denosumab
discontinuation (5.9%, n = 35), and loss to follow-up (4.3%,
n = 26). At week 48, 387 (64.7%) were still under observation
and 211 (35.3%) had discontinued the study prematurely. The
median (Q1, Q3) duration of study-related observation was
48 weeks (27.3, 49.9). After the end of the study-related ob-
servation period, 379 patients (63.4%) continued denosumab
treatment. Overall, 91 patients (15.4%) discontinued
denosumab, 56 patients during observation and 35 after the
end of observation. The documented reasons for discontinua-
tion of denosumab were physician’s decision (n = 29, 4.8%),
patient’s decision (n = 28, 4.7% of FAS), (S)ADRs (n = 8,
1.3%: peripheral edema, hypocalcemia, hypophosphatemia,
osteonecrosis, or cellulitis), switch to other antiresorptive
drugs (n = 5, 0.8%), or other reasons (n = 21, 3.5%). The over-
all number of deaths during the observation period including
safety follow-up was 82 (13.7%), of which 71 patients (11.9%
of FAS) died of their underlying cancer and 11 (1.8% of FAS)
died of other causes not related to denosumab. Details on
patient disposition by cancer type are shown in Table S1 of
the online supplemental material.
Patient demographics
Of patients, 54.2% (n = 324) had breast cancer, 24.4% (n =
146) had prostate cancer, 9.9% (n = 59) had lung cancer,
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Fig. 2 Distribution of tumor
types, overall and by country (%)
Fig. 1 Patient disposition. [a] 634 patients were enrolled; 319 from
Austria, 130 from Bulgaria, 109 from the Czech Republic, 58 from
Slovakia, and 18 from Hungary. Thirty-six patients were excluded from
the analysis. The reasons for exclusion from analysis were violation of
inclusion or exclusion criteria, erroneous double entry in the database, or
entry by mistake, e.g., erroneously entering a training data set in the real
database instead of the training database. [b] Only patients who did not
die and were not lost to follow-up are included in this section
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Table 1 Patient demographics and disease characteristics
Characteristic Breast cancer (N = 324) Prostate cancer (N = 146) Lung cancer (N = 59) Other (N = 69) Total (N = 598)
Age (years)
Mean (SD) 60.6 (12.1) 70.5 (7.7) 62.8 (9.5) 66.3 (9.3) 63.9 (11.4)
Median (Q1, Q3) 61.0 (51.0, 70.0) 72.0 (65.0, 76.0) 65.0 (57.0, 69.0) 66.0 (60.0, 74.0) 65.0 (57.0, 72.0)
Range 30–91 46–87 24–77 46–89 24–91
Age category, n (%)
< 65 197 (60.8) 32 (21.9) 27 (45.8) 30 (43.5) 286 (47.8)
≥ 65 127 (39.2) 114 (78.1) 32 (54.2) 39 (56.5) 312 (52.2)
< 75 286 (88.3) 99 (67.8) 56 (94.9) 56 (81.2) 497 (83.1)
≥ 75 38 (11.7) 47 (32.2) 3 (5.1) 13 (18.8) 101 (16.9)
Gender, n (%)
Male 2 (0.6) 146 (100.0) 34 (57.6) 40 (58.0) 222 (37.1)
Female 322 (99.4) 0 25 (42.4) 29 (42.0) 376 (62.9)
ECOG status, n (%)
0 194 (59.9) 70 (47.9) 22 (37.3) 28 (40.6) 314 (52.5)
1 108 (33.3) 67 (45.9) 34 (57.6) 33 (47.8) 242 (40.5)
2 22 (6.8) 9 (6.2) 3 (5.1) 8 (11.6) 42 (7.0)
Time since cancer diagnosis (months)
N 322 145 59 69 595
Mean (SD) 63.9 (77.7) 30.9 (48.3) 4.7 (7.6) 39.0 (48.2) 47.1 (67.1)
Median (Q1, Q3) 35.9 (4.0, 94.5) 8.8 (2.1, 34.4) 1.8 (0.8, 4.6) 17.5 (4.8, 59.0) 19.3 (2.2, 65.0)
Range[a] 0.0–400.4 − 0.1–258.6 0.1–42.3 − 0.13–219.4 − 0.13–400.4
Missing 2 1 0 0 3
Time since cancer diagnosis category, n (%)
< 1 year 105 (32.4) 79 (54.1) 54 (91.5) 25 (36.2) 263 (44.0)
1–< 2 years 25 (7.7) 15 (10.3) 3 (5.1) 14 (20.3) 57 (9.5)
2–< 5 years 77 (23.8) 28 (19.2) 2 (3.4) 14 (20.3) 121 (20.2)
5–< 10 years 60 (18.5) 13 (8.9) 0 (0) 11 (15.9) 84 (14.0)
10–< 20 years 42 (13.0) 8 (5.5) 0 (0) 5 (7.2) 55 (9.2)
≥ 20 years 13 (4.0) 2 (1.4) 0 (0) 0 (0) 15 (2.5)
Missing 2 (0.6) 1 (0.7) 0 (0) 0 (0) 3 (0.5)
Metastasis site, n (%)
Bone only 128 (39.5) 113 (77.4) 20 (33.9) 18 (26.1) 279 (46.7)
Bone and other 196 (60.5) 33 (22.6) 39 (66.1) 51 (73.9) 319 (53.3)
Number of bone metastases category, n (%)
1 39 (12.0) 12 (8.2) 13 (22.0) 21 (30.4) 85 (14.2)
2–4 73 (22.5) 27 (18.5) 19 (32.2) 20 (29.0) 139 (23.2)
> 4 171 (52.8) 94 (64.4) 26 (44.1) 20 (29.0) 311 (52.0)
Unknown 41 (12.7) 13 (8.9) 1 (1.7) 8 (11.6) 63 (10.5)
Non-bone metastases site[b], n (%)
Liver 81 (25.0) 6 (4.1) 16 (27.1) 26 (37.7) 129 (21.6)
Lung 80 (24.7) 6 (4.1) 14 (23.7) 21 (30.4) 121 (20.2)
Brain 11 (3.4) 0 (0) 7 (11.9) 4 (5.8) 22 (3.7)
Other 96 (29.6) 28 (19.2) 23 (39.0) 24 (34.8) 171 (28.6)
Time since metastasis diagnosis (months)
N 324 142 59 68 593
Mean (SD) 7.2 (22.5) 6.2 (12.0) 3.0 (6.2) 10.1 (16.8) 6.9 (18.7)
Median (Q1, Q3) 1.1 (0.5, 3.5) 1.7 (0.7, 5.8) 1.4 (0.6, 3.3) 2.7 (0.7, 12.1) 1.3 (0.6, 4.4)
Range 0.0–214.7 0.0–74.2 0.1–42.3 0.0–78.8 0.0–214.7
Missing 0 4 0 1 5
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and 11.5% (n = 69) had cancers summarized as “other”.
Figure 2 shows the distribution of cancer types by country.
Most patients were female (62.9%, n = 376), owing to the
large number of patients with breast cancer (Table 1). The
median age was 65.0 years (range 24–91); 52.2% (n = 312)
was 65 years or older. Age differed by cancer type with the
proportion of patients aged 75 or older ranging from 5.1%
of patients with lung cancer (n = 3) to 32.2% of patients
with prostate cancer (n = 47). ECOG performance status
was 0 in 52.5% of patients (n = 314), 1 in 40.5% (n =
242), and 2 in 7.0% (n = 42).
Disease characteristics
The median (Q1, Q3) time since cancer diagnosis was
19 months (2.2, 65.0) with 44.0% of patients (n = 263) receiv-
ing the diagnosis for cancer less than 1 year before enrollment.
The median time since diagnosis ranged from 1.8 months in
lung cancer patients to 35.9 months in breast cancer patients
(Table 1). Patients were required to have confirmed metastatic
disease. The median time since diagnosis of metastatic disease
was 1month (IQR 0.6, 4.4), and in 86.6% of patients (n = 518)
metastatic disease was diagnosed less than 1 year before en-
rollment. By metastasis site, 46.7% (n = 279) had bone metas-
tases only and 53.3% (n = 319) had metastases in the bone and
other sites. Other metastatic sites were in the liver in 21.6% of
patients (n = 129), lung in 20.2% (n = 121), brain in 3.7% (n =
22), and other sites in 28.6% (n = 171). Patient could have
metastases in more than one site. Bone metastases were diag-
nosed less than 1 year before enrollment in 93.0% of patients
(n = 556) and were mostly asymptomatic and diagnosed by
imaging (72.9%, n = 436; Table 1). The median time between
diagnosis of bone metastases and initiation of denosumab was
1.3 months (IQR 0.6, 4.4).
Table 1 (continued)
Characteristic Breast cancer (N = 324) Prostate cancer (N = 146) Lung cancer (N = 59) Other (N = 69) Total (N = 598)
Time since metastasis diagnosis category, n (%)
<1 year 287 (88.6) 124 (84.9) 57 (96.6) 50 (72.5) 518 (86.6)
1–< 2 years 15 (4.6) 6 (4.1) 1 (1.7) 9 (13.0) 31 (5.2)
2–< 5 years 15 (4.6) 10 (6.8) 1 (1.7) 6 (8.7) 32 (5.4)
5–< 10 years 3 (0.9) 2 (1.4) 0 (0) 3 (4.3) 8 (1.3)
10–< 20 years 4 (1.2) 0 (0) 0 (0) 0 (0) 4 (0.7)
≥ 20 years 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Missing 0 (0) 4 (2.7) 0 (0) 1 (1.4) 5 (0.8)
Time since bone metastasis diagnosis (months)
N 323 142 59 68 592
Mean (SD) 3.3 (12.2) 4.8 (9.0) 1.9 (3.3) 3.2 (6.8) 3.5 (10.4)
Median (Q1, Q3) 0.8 (0.3, 2.0) 1.5 (0.7, 4.6) 1.1 (0.4, 2.2) 0.8 (0.3, 2.3) 1.0 (0.4, 2.5)
Range 0.0–143.5 0.0–54.2 0.0–23.4 0.0–41.5 0.0–143.5
Missing 1 4 0 1 6
Time since bone metastasis diagnosis categories, n (%)
<1 year 306 (94.4) 127 (87.0) 58 (98.3) 65 (94.2) 556 (93.0)
1–< 2 years 10 (3.1) 6 (4.1) 1 (1.7) 0 (0) 17 (2.8)
2–< 5 years 5 (1.5) 9 (6.2) 0 (0) 3 (4.3) 17 (2.8)
5–< 10 years 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
10–< 20 years 2 (0.6) 0 (0) 0 (0) 0 (0) 2 (0.3)
≥ 20 years 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Missing 1 (0.3) 4 (2.7) 0 (0) 1 (1.4) 6 (1.0)
Diagnosis method of bone metastasis, n (%)
By symptoms 81 (25.0) 35 (24.0) 21 (35.6) 17 (24.6) 154 (25.8)
Asymptomatic/imaging 237 (73.1) 111 (76.0) 38 (64.4) 50 (72.5) 436 (72.9)
Unknown 6 (1.9) 0 (0) 0 (0) 2 (2.9) 8 (1.3)
Percentages are based on the number of patients in full analysis set
[a] Negative values are from the following two patients: Patient 1, first XGEVA dose: 2014-07-16, cancer diagnosis date: 2014-07-18. Patient 2, first
XGEVA dose: 2015-11-05, cancer diagnosis date: 2015-11-09
[b] Percentages in this section may add up to more than 100% because one patient may have different metastasis sites
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Prior skeletal-related events
Prior to enrollment, SREs were confirmed in 10.9% of pa-
tients (n = 65): 7.5% (n = 45) had pathological fractures,
2.2% (n = 13) required radiation to the bone, 1.5% (n = 9)
had surgery to the bone, and 0.5% (n = 3) had spinal cord
compression. The time between diagnosis of an SRE and en-
rollment was less than 3 months in 7.4% of patients (n = 44)
and between 3 and 6 months in 2.3% (n = 14); in 2 patients
(0.3%), it was between 6 and 12 months, and in 5 patients
(0.8%), it was longer than 12 months.
Anticancer therapies
In the metastatic setting, 35.3% of patients (n = 211) had re-
ceived chemotherapy prior to starting denosumab, 32.8% (n =
196) had received previous endocrine therapy, 14.4% (n = 86)
radiotherapy, and 7.9% (n = 47) surgery. During the study ob-
servation period and concomitantly with denosumab, 52.3%
of patients (n = 313) received chemotherapy, 46.3% (n = 277)
endocrine therapy, 15.7% (n = 94) radiotherapy, and 3.5%
(n = 21) surgery.
Denosumab treatment rationale and duration
Prior to starting denosumab, 7.7% of patients (n = 46) had
received other antiresorptive agents. Previous antiresorptive
therapies were zoledronic acid (6.2%, n = 37), ibandronate
(0.3%, n = 2), pamidronate (0.3%, n = 2), and unspecified
others (0.8%, n = 5). Antiresorptive agents were mainly ad-
ministered intravenously (6.7%, n = 40); 1.0% (n = 6) re-
ceived them per os. All 46 patients received their
antiresorptive therapy for 6 months or less, as per inclusion
criteria. Reasons for not continuing previous antiresorptive
therapies were intolerability in 1.5% (n = 9), patient’s wish
(0.5%, n = 3), or physician decision (5.7%, n = 34).
Physicians decided to stop the previous antiresorptive agents
because of the route of administration (3.3%, n = 20), renal
insufficiency (1.5%, n = 9), or unspecified other reasons
(1.2%, n = 7).
The most frequent physician-reported reasons for the
choice of denosumab were the prevention of first SRE
(63.5%, n = 380; first most important), superior efficacy of
denosumab (28.3%, n = 169, secondmost important), and bet-
ter safety profile of denosumab (15.6%, n = 93; third most
important).
The patients received a median (Q1, Q3) of 11 doses (6.0,
12.0) of denosumab over a period of 309 days (168.0, 319.0).
Calcium and vitamin D supplementation
The median (Q1, Q3) serum calcium level at enrollment was
2.35 (2.25, 2.44) mmol/L. At the second dose of denosumab,
the serum calcium level reached a nadir at 2.26 (2.15, 2.37)
mmol/L. Serum calcium remained above this lowest value
from the third dose onwards throughout the study. At enroll-
ment, 70.2% of patients (n = 420) received calcium supple-
mentation and 71.4% (n = 427) received vitamin D supple-
mentation. This proportion increased to approximately 80%
at dose 2 and steadily decreased thereafter (Fig. S1, online
supplemental material).
Persistence at 24 weeks (primary outcome measure)
Persistence at week 24 was 62.6% (95% CI 58.4, 66.7) over-
all, and ranged between 26.1% for lung cancer and 69.5% for
breast cancer, and between 56.0% for Austria and 84.8% for
Slovakia. Figures 3 and 4 show persistence at 24 weeks by
tumor type and by country, respectively.
Fig. 3 Persistence for denosumab
at 24 weeks, overall and by tumor
type (%, 95% CI)
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Persistence differed by tumor type, impacting on persis-
tence in the countries. In Austria and Slovakia, the largest
group of represented tumors was breast cancer; in Hungary,
only prostate cancer patients were enrolled. In the
Czech Republic and Bulgaria, breast and prostate cancer pa-
tients were almost equally represented and formed the largest
groups (Fig. 2).
Persistence at 48 weeks
Persistence at 48 weeks was 40.1% (95% CI 35.9, 44.4).
Patterns by tumor type and by country were similar to the
persistence results for week 24.
Time to non-persistence
The Kaplan-Meier (KM) median (95% CI) time to non-
persistence was 274.0 (232.0, 316.0) days, with 317.0
(263.0, 335.0) in breast cancer, 325.0 (271.0, 344.0) in pros-
tate cancer, 118.0 (59.0, 144.0) in lung cancer, and 118.0
(57.0, 230.0) in other cancers.
An analysis of median time to non-persistence by pre-
vious antiresorptive therapy (y/n) showed a KM median
(95% CI) of 294.0 days (168.0, 344.0) for 46 patients with
previous antiresorptive therapy and 273.0 days (232.0,
316.0) for 552 patients with no previous antiresorptive
therapy.
Using a Cox proportional hazards model, tumor type
(breast versus other, prostate versus other), previous anti-
neoplastic therapy (y/n), and ECOG status (0 versus 2)
were found to be significantly associated with time to
non-persistence with denosumab (all factors with
p < 0.05, Wald test).
Reasons for non-persistence
Documented reasons for non-persistence were premature ter-
mination of denosumab therapy, an ADR, withdrawal of in-
formed consent, an insufficient number of injections (week 48
only), and unspecified other reasons. Figure 5 shows reasons
for non-persistence at weeks 24 and 48. Missing permissible
injection intervals were documented as the most frequent rea-
son for non-persistence at week 24 as well as week 48 (see
“Methods” section for definitions). In the sensitivity analysis
(see online supplement for methods), extending the permissi-
ble time windows between injections and week 24 and 48,
respectively, as described earlier, increased the proportion of
persistent patients by more than 10%.
Pain management
Overall, the requirements for strong analgesics were generally
low. The proportion of patients not requiring any analgesics
remained stable at approximately 60% of patients with avail-
able values at the respective timepoints. When receiving pain
medication at baseline, most patients received non-opioid an-
algesics (20.2%, n = 121; AQA score 1) or strong opioids at a
low daily dose of < 75 mg oral morphine equivalents (11.4%,
n = 68; AQA score 3). When assessing the shift in analgesic
use among patients with no or weak opioid analgesics (AQA
score ≤ 2) at baseline, very few patients shifted to an AQA
category > 2 (i.e., strong opioids at increasing doses) at later
timepoints (Fig. 6).
Safety
Only ADRs considered related to denosumab by the treating
physician were collected. Overall, 10.2% of patients (n = 61)
Fig. 4 Persistence for denosumab
at 24 weeks, overall and by
country (%, 95% CI)
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experienced an ADR. The most frequently reported ADR was
hypocalcemia (7.4%, n= 44). Ten patients (1.7%) experienced
ADRs leading to discontinuation of denosumab. Serious ADRs
were documented for 1.3% of patients (n = 8). ONJ was docu-
mented in 0.7% of patients (n= 3). Themedian (IQR) duration to
first ONJ event based on these three patients was 165.0 days
Fig. 5 Reasons for non-persistence for denosumab at 24 weeks, overall and by country (%) (S)ADR, (serious) adverse drug reaction; permissible time
windows between injections of a maximum of 35 days were defined by the protocol
Fig. 6 Proportion of patients with AQA score ≤ 2 at baseline shifting to AQA score > 2 at later denosumab doses
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(105.0, 298.0). Other reported serious ADRswere costovertebral
angle tenderness, pain, hypocalcemia, peripheral edema, dys-
pnea, swelling face, and cellulitis (n = 1, respectively). No fatal
ADRs occurred. Overall, the exposure-adjusted incidence rate
was 0.187 (95% CI 0.147, 0.235) for ADRs per 100 patient-
years and 0.027 (95% CI 0.014, 0.049) for serious ADRs.
Discussion
In the present study, 62.6% of patients demonstrated regular
and continuous use of denosumab, i.e., persistence, over
24 weeks and 40.1% over 48 weeks. The most frequent reason
for non-persistence was a delay in drug administration. Only
4.8% of patients stopped denosumab treatment following the
decision of their treating physician. In the similarly designed
German X-TREME study, the final analysis on 1008 patients,
included in the persistence assessment, showed persistence
with denosumab at week 24 of 61.5%. Persistence at week
48 was 37.7%. These findings are very similar to the results
of the present study. The proportion of patients persistent with
denosumab at 24 weeks was previously assumed at 60%
based on phase III studies [6, 9–11]. The observed persistence
at 24 weeks found in this study (62.6%) was thus very similar
to previous estimates.
In a retrospective analysis of a German sick fund claims da-
tabase including 1156 adult patients with solid tumors newly
diagnosed with bone metastases and receiving denosumab or
bisphosphonates, persistencewas defined as continuous prescrip-
tions with < 90-days gaps. Of patients with breast, prostate, and
lung cancer, respectively, 25%, 17%, and 20% had prior SREs.
For breast cancer, persistence at 1 year, according to the above
definition, was 78% for denosumab and 58%, 56%, and 54% for
ibandronate, pamidronate, and zoledronate, respectively. For
prostate cancer, persistence with denosumab and zoledronate
were 58% and 50%, respectively. Finally, in lung cancer, persis-
tence for denosumab, pamidronate, and zoledronate was 68%,
34%, and 60%, respectively. Persistence was lower in a sensitiv-
ity analysis in which the definition of persistence was stricter,
applying 60-day gaps/windows. The definition of persistence
differed between these studies and was substantially stricter in
the present study because the German sick fund study did not
consider persistence for each of the individual once in a month
administrations and missing the recommended administration
interval once was the most important reason for non-persistence.
The incidence of osteonecrosis was 0.5% in the present study
(n= 3), with two confirmed cases of ONJ and one with unspec-
ified location. In the German X-TREME study, 15 patients with
suspected ONJ (1.3%) were reported. In randomized controlled
studies of denosumab, 2% of breast cancer patients, 2.3% of
prostate cancer patients, and 1.1% of patients with either a solid
tumor or multiple myeloma experienced ONJ [9–11].
This was an observational study with all limitations inher-
ent to the study design, especially selection and reporting bias,
and lack of blinding and of a control group. Persistence was
estimated taking all drop-outs related to denosumab into ac-
count. Impact of bias was addressed in sensitivity analyses.
The extension of the allowed time windows was the only
factor that had an impact on results in the sensitivity analyses.
Importantly, missing the recommended administration inter-
val was also the most important reason for non-persistence.
The sensitivity analyses revealed that the different ways of
handling drop-outs did not change the results of the primary
and secondary outcome measure. The subgroup analyses by
tumor type and by country revealed some differences in per-
sistence, which limit generalizability of the results to other
tumors, countries, and regions. An analysis of the distribution
of tumor types by country revealed that differences between
countries can at least in part be explained by the different
distributions of tumors in each country. Another difference
between countries is the method of dispensation of
denosumab to the patients. In Austria, denosumab was mainly
dispensed as a retail product at the time of study; in Hungary,
it was available as a retail product and reimbursed in prostate
cancer only. In Czech Republic and Bulgaria, it was adminis-
tered exclusively in hospitals. In Slovakia, it was a retail prod-
uct during the first part of the study and a hospital product as
of October 2016. Patients received a diary to report each ad-
ministration of denosumab. Especially in countries where
denosumab was distributed as a retail product and not exclu-
sively administered in the hospital, patient self-reporting may
be prone to inaccuracies.
Conclusions
The majority of patients were persistent with a once in a
month administration of denosumab for over 24 weeks. The
type of primary tumor, previous antineoplastic therapy, and
ECOG status appeared to influence persistence. The most fre-
quent reason for non-persistence was the violation of admin-
istration intervals. Most patients reported taking calcium and
vitamin D supplementation as recommended as per label. The
incidence of ADRs, especially of ONJ, was in line with ex-
pectations from previous studies.
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